Amgen Cancer Drug Combo Cuts Death Risk by 58%
A new drug combination from Amgen and AstraZeneca gives lung cancer patients more time to live.
Lung cancer steals time from thousands of families every year. One aggressive type spreads fast and gives doctors few good options. Now, a new treatment offers fresh hope.
Drugmaker Amgen tested its medicine alongside a drug from AstraZeneca. The pair worked together to fight the tumors. Patients who took both medicines cut their risk of death by 58%.
Doctors call this a major step forward for lung cancer care. Patients lived longer compared to standard treatments. The medicine trains the immune system to hunt down cancer cells.
Medical breakthroughs like this change lives and drive biotech growth. Better treatments bring hope to families who need answers.
Source: CNBC
More from Biotech
